EQ — Equillium, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1746466 ·
Last close
$2.32
Market Cap
$146.69M
52W High
$2.70
52W Low
$1.60
ADV30
334,745
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,610,000 | -5,311,000 | 63,083,000 | 61,322,000 | 3,596,000 |
| Dec 2025 | 0 | — | -3,962,000 | -3,775,000 | 31,887,000 | 30,277,000 | 3,290,000 |
| Sep 2025 | 0 | — | -4,575,000 | -4,230,000 | 34,506,000 | 33,120,000 | 3,567,000 |
| Jun 2025 | 0 | — | -6,228,000 | -5,739,000 | 12,399,000 | 11,495,000 | 7,343,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,746,000
Investing CF
$4,464,000
Financing CF
$30,427,000
CapEx
$-52,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.50
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-216,205,000
Inventory
—
Receivables
$108,000
ST Investments
$0
EBIT TTM
$-23,635,000
Pretax Income TTM
$-22,398,000
Interest Exp TTM
$0
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,634,000 | -22,398,000 | 31,887,000 | 3,290,000 | — | -22,746,000 |
| Dec 2024 | 41,095,000 | -8,269,000 | -8,067,000 | 25,604,000 | 6,543,000 | — | -19,026,000 |
| Dec 2023 | 36,084,000 | -14,522,000 | -13,335,000 | 50,530,000 | 27,957,000 | — | -21,783,000 |
| Dec 2022 | 15,759,000 | -39,027,000 | -62,428,000 | 78,421,000 | 46,479,000 | — | -8,733,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.26
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $146.55M | $7.91 | — |
| SLNCF | Silence Therapeutics plc | $150.21M | $1.06 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $142.95M | $12.51 | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $142.60M | $51.81 | — |
| ASRT | Assertio Holdings, Inc. | $151.60M | $23.46 | — |
News headlines (Yahoo Finance, 1h cache)
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
2026-05-20 20:05 · Yahoo
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-13 20:01 · Yahoo
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 20:42 · Yahoo
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
2026-04-20 20:05 · Yahoo
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
2026-04-08 12:30 · Yahoo
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
2026-03-25 20:05 · Yahoo
Here’s What Roth Capital Thinks of Equillium (EQ) Stock
2026-03-24 21:38 · Yahoo
Equillium to Participate in the 38th Annual Roth Conference
2026-03-18 12:30 · Yahoo
Equillium Announces $35 Million Financing with RA Capital Management
2026-03-13 12:00 · Yahoo
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
2026-02-25 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.